

AMENDMENTS

In the Specification:

Please insert the following paragraph starting on page 1 at line 5

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to PCT/CA00/00388 filed April 7, 2000 which claims priority to provisional application nos. 60/128,559 filed April 9, 1999 and 60/179,743 filed February 2, 2000, all of which are hereby incorporated in their entirety by reference.

In the Claims:

Please amend the following claims.

13. (Amended) The method of claim 12, wherein said eIF-4E sequestering agent comprises a sequence having an amino acid sequence selected from YxxxxL ϕ , Yx+xf $\phi\phi$, + ϕ xYx+xf $\phi\phi$, + $\phi\phi$ Y-+xF/A $\phi\phi$ xxRxSP, and + $\phi\phi$ Y-+xfL ϕ xxRxSP, or + ϕ xYx+xfL ϕ xxxxxx wherein + and - refer to a charged amino acid; ϕ is a hydrophobic amino acid; x is any amino acid; and the capital letters refer to the known one letter code for amino acids.

17. (Amended) A method of identifying an agent which modulates glucose and/or fat metabolism *in vivo* comprising:

- a) providing a translationally active preparation of translation factors and at least one mRNA having a cap structure whose translation is cap-dependent;
- b) measuring the initiation of translation on said mRNA, or the binding of at least some translation factors of a) to said cap of said mRNA in the presence and in the absence of an agent suspected of modulating the translation efficiency of cap-dependent mRNAs or the binding of translation factors to the cap structure thereof, thereby identifying an agent which modulates cap-dependent translation and wherein a difference in the translation activity and/or binding in the presence of the agent, as compared to that in the absence thereof identifies said agent as a modulator of cap-dependent translation;
- c) administering said agent identified in b) to an animal; and

Q3
d) measuring glucose and/or lipid levels in the animal of step c) and comparing same with that of a control animal, not having been administered said agent, wherein a difference in glucose and/or lipid levels of the animal of step c) as compared to that of the control animal identifies said agent as a modulator of glucose or fat metabolism *in vivo*.

Q4
21. (Amended) A modulator of glucose or fat metabolism *in vivo* identified by the method of claim 17.

Q5
31. (Amended) A modulator of glucose or fat metabolism *in vivo* identified by the method of claim 28.

Q6
38. (Amended) A modulator of glucose and/or fat metabolism *in vivo* identified by the method of claim 7.

SEARCHED
INDEXED
SERIALIZED
FILED
APR 12 2003
U.S. PATENT AND TRADEMARK OFFICE